Drs. Potts and Kronenberg are responsible for overall direction of the projects and cores of this program project. They meet regularly, together and with principal investigators and core directors, to discuss ongoing research and to assure continuous integration of work by all participating groups. Further, as scientific opportunities arise, Drs. Potts and Kronenberg coordinate the modifications of aims and goals of each project and encourage new collaborative opportunities. To facilitate close interactions among participants in the program project and to share information with groups of other scientists whose research complements our own, regular research meetings are planned. The responsiveness and quality of the work of the core facilities are carefully monitored. Each week four meetings, open to all staff members and regularly attended by participants in this program project, are held within the Endocrine Unit. Drs. Potts and Kronenberg plan the topics to be discussed each week. The purpose of these informal and very interactive meetings is to present new ideas and seek input from colleagues about ongoing research. In addition, three journal clubs, each focused on a specific area pertinent to the Program Project (Gene Regulation & Development, Cell Signaling, and Clinical Research) meet weekly to discuss recent publications related to those topics. In addition, monthly meetings are held with four different groups of scientists from outside the Endocrine Unit (the MGH Renal Unit, scientists in the Center for Regenerative Medicine led by Dr. David Scadden, colleagues from the Harvard School of Dental Medicine and Harvard School of Public Health, and scientists in the Genetics Department at Harvard Medical School). These meetings provide critical forums for the sharing of information within the wider research community. All have attracted increasing interest from scientists within and outside MGH, expanding the range of topics presented and encouraging broader collaborations. The careful planning of Drs. Potts and Kronenberg is responsible for the success of these monthly meetings. Another vital function of the Core Directors is fiscal oversight for the program project. Centralization of administrative support functions necessary for monitoring program project resources is more cost-effective and efficient than distributing those responsibilities among the individual projects and cores. Reporting requirements, compliance with hospital and government regulations, and careful budgeting of expenses to prevent cost overruns help to assure that resources are appropriately allocated. These vital functions performed with direction from Drs. Potts and Kronenberg.

Agency
National Institute of Health (NIH)
Type
Research Program Projects (P01)
Project #
5P01DK011794-49
Application #
9170965
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
Budget End
Support Year
49
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02114
Bi, Ruiye; Fan, Yi; Lauter, Kelly et al. (2016) Diphtheria Toxin- and GFP-Based Mouse Models of Acquired Hypoparathyroidism and Treatment With a Long-Acting Parathyroid Hormone Analog. J Bone Miner Res 31:975-84
Stevenson, Hilary P; Lin, Guowu; Barnes, Christopher O et al. (2016) Transmission electron microscopy for the evaluation and optimization of crystal growth. Acta Crystallogr D Struct Biol 72:603-15
Ono, Noriaki; Kronenberg, Henry M (2016) Bone repair and stem cells. Curr Opin Genet Dev 40:103-107
Kim, Sang Wan; Lu, Yanhui; Williams, Elizabeth A et al. (2016) Sclerostin Antibody Administration Converts Bone Lining Cells into Active Osteoblasts. J Bone Miner Res :
Wein, Marc N; Liang, Yanke; Goransson, Olga et al. (2016) SIKs control osteocyte responses to parathyroid hormone. Nat Commun 7:13176
Eda, Homare; Santo, Loredana; Wein, Marc N et al. (2016) Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease. J Bone Miner Res 31:1225-34
Sinha, Partha; Aarnisalo, Piia; Chubb, Rhiannon et al. (2016) Loss of Gsα in the Postnatal Skeleton Leads to Low Bone Mass and a Blunted Response to Anabolic Parathyroid Hormone Therapy. J Biol Chem 291:1631-42
Tenhola, Sirpa; Voutilainen, Raimo; Reyes, Monica et al. (2016) Impaired growth and intracranial calcifications in autosomal dominant hypocalcemia caused by a GNA11 mutation. Eur J Endocrinol 175:211-8
Cheloha, Ross W; Watanabe, Tomoyuki; Dean, Thomas et al. (2016) Backbone Modification of a Parathyroid Hormone Receptor-1 Antagonist/Inverse Agonist. ACS Chem Biol 11:2752-2762
Hattersley, Gary; Dean, Thomas; Corbin, Braden A et al. (2016) Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling. Endocrinology 157:141-9

Showing the most recent 10 out of 195 publications